Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Purple Biotech ( (PPBT) ) is now available.
On September 10, 2025, Purple Biotech announced that the European Patent Office intends to grant a patent for NT219 combinations with immunotherapies or MEK inhibitors, which could enhance treatment responsiveness in resistant cancers. This patent, expected to last until 2036, underscores Purple Biotech’s strategic positioning in the oncology sector, potentially expanding its market impact and offering new treatment avenues for resistant tumors.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. Its oncology pipeline includes CAPTN-3, CM24, and NT219, with a focus on innovative mechanisms such as tri-specific antibodies and dual inhibitors targeting key cancer pathways.
Average Trading Volume: 965,723
Technical Sentiment Signal: Sell
Current Market Cap: $5.58M
For detailed information about PPBT stock, go to TipRanks’ Stock Analysis page.